AMAmgen AMGN · NASDAQ
$432.49 -0.35% (-$1.54)
- Market cap
- $233.8B
- Enterprise value
- $277.1B
- P/E
- 26.7x
- Forward P/E
- 18.7x
- PEG
- 0.3x
- P/S
- 6.1x
- P/FCF
- 23.0x
- EV/EBITDA
- 16.8x
- ROIC
- 14.2%
- Gross margin
- 72.7%
- Net margin
- 22.9%
- Dividend yield
- 2.30%
- Payout ratio
- 61.5%
- Net debt/EBITDA
- 2.6x
- Beta
- 0.41
- Free float
- 99.7%
About the company
Amgen Inc. is an American biotechnology company specializing in research, development, and manufacturing of biologic medicines. The company focuses on innovative therapeutic treatments for various diseases, including cancer, cardiovascular conditions, arthritis, and other serious illnesses. Amgen has developed a range of successful drugs that have transformed the lives of patients worldwide. The company also invests in research for new drugs and treatment approaches to better address current and future healthcare challenges. Amgen collaborates with physicians, scientists, and other experts to improve healthcare and develop new therapeutic options. Amgen Inc. (AMGN) shares are an interesting choice for investors who follow the biotechnology sector and seek investment opportunities in a reputable company that brings innovative therapeutic treatments for serious diseases.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Bradway
Employees
31,500
Headquarters
Thousand Oaks
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number